Shots:

• The companies collaborated to provide GSK with additional capacity to manufacture and supply GSK’s innovative biopharmaceutical therapies. The eight-year contract is valued at more than $231M
• This capacity will be flexible depending on GSK’s future needs and will supplement GSK’s existing manufacturing network
• Samsung Biologics will commercially produce GSK's Benlysta (belimumab) with technology transfer starting in 2020 and the first commercial supply expected in 2022. The focus is to expand the agreement to additional specialty-care products in the future

Click here ­to­ read full press release/ article 

Ref: GSK | Image: GSK